APBMT 2026 | GoBroad Healthcare Group to Present 20 Studies in HSCT and Cellular Therapy

The 31st Annual Congress of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT 2026) will be held in Manila, the Philippines, from October 1 to 4, 2026.

At this year’s congress, GoBroad Healthcare Group (GHG) will present 20 studies, including 2 oral presentations, 17 posters, and 1 e-poster, covering hematopoietic stem cell transplantation (HSCT), CAR-T cell therapy, complex hematologic diseases, post-transplant complications, immune reconstitution, and specialized nursing care.

Oral Presentations

Relapse Dominates Treatment Failure After Allogeneic Transplantation in WT1-Mutated Hematologic Malignancies

Presenter: Zhihui Li

Corresponding Author: Tong Wu

Institution: Beijing GoBroad Boren Hospital

The study investigates treatment outcomes and patterns of failure after allogeneic HSCT in patients with WT1-mutated hematologic malignancies, with a particular focus on post-transplant relapse.

CD7-CAR-T Therapy Bridged to Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Patients with Refractory/Relapsed T-ALL/LBL

Presenter: Dongfang Yang

Corresponding Authors: Tong Wu, Yongqiang Zhao

Institution: Beijing GoBroad Boren Hospital

This study explores CD7 CAR-T therapy followed by allogeneic HSCT in pediatric patients with refractory or relapsed T-ALL/LBL, providing further clinical evidence for sequential treatment strategies in high-risk T-cell malignancies.

Broad Clinical and Translational Research Portfolio

The 18 poster and e-poster presentations span several areas of current clinical interest, including:

• allogeneic HSCT in elderly AML and TP53-mutated B-ALL;
• second transplantation in acute lymphoblastic leukemia;
• immune reconstitution after allo-HSCT in extranodal NK/T-cell lymphoma;
• longitudinal single-cell analysis after sequential CAR-T therapy;
• immune microenvironment changes following CAR-T therapy in refractory large B-cell lymphoma;
• CD7 CAR-T therapy in mixed phenotype acute leukemia;
• conditioning strategies for hemophagocytic lymphohistiocytosis;
• vascular access, wound care, GVHD management, stem cell collection, and specialized nursing in transplant patients.

These studies reflect GoBroad’s ongoing efforts to address practical clinical questions through real-world experience, translational research, and multidisciplinary care.

Through APBMT 2026, GoBroad looks forward to exchanging clinical experience and research insights with international colleagues and contributing further evidence from Chinese clinical practice to the advancement of hematology, stem cell transplantation, and cellular therapy.